This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas L. Ray, MD

Arch Dermatol. 1990;126(10):1347-1350.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Decoste et al¹ report on transfusion-associated graft-vs-host disease (GVHD) in this issue of the ARCHIVES and raise important considerations for dermatologists evaluating morbilliform erythemas and exanthems. In healthy individuals, such eruptions are frequently attributed (correctly or otherwise) to a drug sensitivity or reaction, often on criteria of history and temporal association. Occasionally, infectious origins are delineated by more objective criteria. Transient erythemas after a transfusion may be attributed to suspected minor mismatches in blood types, if no other cause is found. However, dermatologists must consider an infrequent but catastrophic process in patients with malignancy or immune deficiency, and even in immunocompetent patients, who receive blood or blood component transfusions.

Graft-vs-host disease acquired from nonirradiated blood transfusions is a well-recognized and usually fatal complication, reported mostly in patients with malignancies. It manifests as a fever, preceding or associated with a morbilliform or follicular erythema, followed by erythroderma, elevated values for . . . [Full Text PDF of this Article]

Author Affiliations
Department of Dermatology University of Iowa College of Medicine Iowa City, IA 52242

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?